Many patients with Afib and high stroke risk are not anticoagulated

In this retrospective analysis of over 170,000 patients with Afib, of the 18% who were at high risk of stroke (CHADS2 score of 3-6), only 42% of them were receiving anticoagulation with warfarin. The % on warfarin was not much different from those in low risk group (CHADS2 score of 0; 40% were on warfarin) or in the moderate risk group (CHADS2 score of 1-2; 44% were on warfarin). Only about a third of patients in each group received continuous warfarin for 6 months. This study highlights the inadequacies of treating high risk stroke patients with warfarin therapy, and the difficulties in keeping them on continuous therapy (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment